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Abstract  21 
Background: 22 
Electronic prescribing (EP) and electronic hospital pharmacy (EHP) systems are increasingly 23 
common. A potential benefit is the extensive data in these systems that could be used to 24 
support antimicrobial stewardship, but there is little information on how such data are 25 
currently used to support the quality and safety of antimicrobial use. 26 
Objectives: 27 
To summarise the literature on secondary use of data (SuD) from EP and EHP systems to 28 
support quality and safety of antimicrobial use, to describe any barriers to secondary use, and 29 
to make recommendations for future work in this field. 30 
Methods: 31 
We conducted a systematic search within four databases; we included original research 32 
studies that were (1) based on SuD from hospital EP or EHP systems, and (2) reported 33 
outcomes relating to quality and/or safety of antimicrobial use, and/or qualitative findings 34 
relating to SuD in this context. 35 
Results: 36 
Ninety-four full-text articles were obtained; 14 met our inclusion criteria. Only two described 37 
interventions based on SuD; seven described SuD to evaluate other antimicrobial stewardship 38 
interventions, and five described descriptive or exploratory studies of potential applications 39 
of SuD. Types of data used were: quantitative antibiotic usage data (n=9 studies); dose 40 
administration data (n=3) and user log data from an electronic dashboard (n=1). Barriers 41 
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included data access, data accuracy and completeness, and complexity when using data from 42 
multiple systems or hospital sites.   43 
Conclusions: 44 
Literature suggests that SuD from EP and EHP systems is potentially useful to support or 45 
evaluate antimicrobial stewardship activities; greater system functionality would help realise 46 
these benefits.   47 
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Introduction 48 
Increasing antimicrobial resistance is a global phenomenon, mainly attributable to increases 49 
in antimicrobial consumption in human, veterinary and agricultural sectors. Public health 50 
bodies worldwide advocate the use of antimicrobial stewardship programmes as a strategy to 51 
help combat antimicrobial resistance and curb the selection and proliferation of resistant 52 
micro-organisms. Monitoring antimicrobial consumption is a key component of these 53 
strategies.1-4 54 
The UK Five Year Antimicrobial Resistance Strategy 2013-20185 lists seven key areas that 55 
need to be addressed to tackle the burden of antimicrobial resistance, one of which, 56 
‘optimising prescribing practice’, includes as a priority ‘identifying the optimum 57 
arrangements for recording and reporting of data (including the use of electronic 58 
prescribing), as well as analysis of data on antibiotic use, resistance and clinical outcomes’. 59 
Other large-scale antimicrobial stewardship programs in the US and UK similarly promote 60 
the use of information technology to help monitor antimicrobial usage.1,6  61 
A potential benefit of both electronic prescribing (EP) and electronic hospital pharmacy 62 
(EHP) systems is that data on medication use is recorded as part of the system, creating the 63 
potential for secondary use of data (SuD) to understand, monitor and subsequently improve 64 
antimicrobial use. Although likely to support antimicrobial stewardship, little is known about 65 
the extent to which this potential benefit has been realised. Previous systematic reviews have 66 
focussed on the benefits of using EP to reduce medication errors and adverse drug events7-10 67 
and on the use of clinical decision support systems (CDSS) to support antibiotic use.11 A 68 
more recent review focused on the effectiveness of information technology in general in 69 
improving hospital antimicrobial prescribing but did not specifically include SuD.12 Another 70 
focused on hospital EP systems in promoting appropriate use of antibiotics but examined 71 
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only experimental studies published since 1997, most of which involved prompts and 72 
reminders aimed at individual patient care.13 The authors of this study specifically highlight 73 
the need to more thoroughly explore interventions that draw on SuD as these are likely to 74 
present the biggest returns on investment.13 No systematic review has explored the use of 75 
data from EP and EHP systems for antimicrobial stewardship. 76 
Our objectives were to review the literature on SuD from EP and EHP systems to support 77 
quality and safety of antimicrobial use in the hospital setting, to describe any barriers to 78 
secondary use, and to make recommendations for future work in this field. 79 
Methods 80 
Search Strategy 81 
Our search strategy was based on four facets: (1) electronic data systems and surveillance, (2) 82 
anti-infectives, (3) quality and safety, and (4) hospitals. Following piloting of the sensitivity 83 
and specificity of various search strategies, we used Medical Subject Headings and keywords 84 
for each of the four facets based on the following Boolean logic: (1 AND 2 AND [3 OR 4]) 85 
OR (“secondary use adj4 data”). The final search term was used to help capture articles that 86 
focused on SuD but may not have included the other search terms.  87 
One researcher (NC) conducted the search on 15 August 2014 using the following databases: 88 
International Pharmaceutical Abstracts, Cumulative Index to Nursing and Allied Health 89 
Literature, Medline, and Excerpta Medica (Embase). The full search strategies used for each 90 
database are provided in Table S1. 91 
Inclusion and exclusion criteria 92 
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We defined SuD as “the reuse of aggregated electronic (clinical or operational) data from an 93 
electronic prescribing or electronic hospital pharmacy system for purposes other than direct 94 
patient care or for its original purpose,” (Chaudhry et al 2016, unpublished data).  95 
We included any original research based on SuD from EP and/or EHP systems that included 96 
antimicrobial data and reported safety and/or quality outcomes relating to antimicrobials, 97 
and/or qualitative findings relating to SuD, in the hospital setting. We were primarily 98 
interested in evidence supporting the effectiveness of interventions based on SuD, but also 99 
more broadly in how data from EP and EHP systems were being used to support 100 
antimicrobial stewardship. Reviews, conference proceedings, letters and opinion papers were 101 
excluded, as were studies based on paper-based prescribing or databases other than EP or 102 
EHP. There were no limits by study design, year or country. Table S2 presents full inclusion 103 
and exclusion criteria.  104 
Study selection  105 
One researcher (CM) screened titles and abstracts (or titles only if abstracts were unavailable) 106 
to identify those for potential inclusion.  A sample of the titles and abstracts (n=50) were then 107 
screened by a second (NC) and third reviewer (BDF) and any disagreements resolved through 108 
discussion. For final study selection, the full-text papers were assessed by the primary 109 
reviewer (CM) and those recommended for inclusion plus, any for which there was any 110 
uncertainty were screened independently by NC and BDF. Reference lists of full-text papers 111 
selected for inclusion were screened to identify any further eligible studies.  112 
Data extraction and analysis 113 
An electronic data collection form was completed by CM for each included study. Extracted 114 
data comprised: data collection period, country and setting, type of study, aim/objectives, EP 115 
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/ EHP system, how the data were extracted and used, methods, and main outcomes. Data 116 
from each study were then extracted to inform a descriptive analysis; the anticipated 117 
heterogeneity of the studies precluded meta-analysis. In addition, any reported barriers to 118 
effective SuD were documented. Data extraction was checked by BDF and any discrepancies 119 
resolved via discussion.  120 
The review was conducted and reported according to the Preferred Reporting Items for 121 
Systematic Reviews and Meta-Analysis (PRISMA) guidelines.14 The protocol was registered 122 
with the PROSPERO international prospective register of systematic reviews (registration 123 
CRD42016042955). 124 
 125 
Results 126 
Initial screening of titles and abstracts yielded 233 records from a total of 2,331 de-duplicated 127 
titles/abstracts. Following review by NC and BDF, 92 were identified for full-text review. 128 
Full-text screening of these 92 papers resulted in twelve that met our inclusion criteria. 129 
Reasons for exclusion are provided in Figure 1. Two further studies were identified from 130 
manual review of reference lists, giving a total of fourteen included studies (Table 1).   131 
Characteristics of included studies  132 
Of the fourteen studies, only two described interventions based on SuD,15,16 one was an 133 
uncontrolled before-and-after evaluation of an antimicrobial audit and feedback intervention 134 
and one tested four sequential interventions, one of which involved real time clinical data 135 
dashboards, using interrupted time series analysis (also based on SuD). Seven described the 136 
reuse of EP/EHP data to evaluate other interventions17-23 and five described descriptive or 137 
exploratory studies of SuD24-28. Of the seven evaluative studies, one evaluated a randomised 138 
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controlled trial,17 four were uncontrolled before-and-after studies,18-20,21 two were time series 139 
studies16,23 and one a descriptive evaluation.21  We did not identify any qualitative studies that 140 
met our inclusion criteria.   141 
The majority of studies (eight)17-22,25-26 were conducted in the USA. Three were from the 142 
UK,16,23,27 and one each from Germany,24 South Korea28 and Australia.15 The majority 143 
(eleven) were single-centre studies.15-24,28 Three specifically focused on paediatric 144 
hospitals.19-20,25  145 
Type of data used 146 
Most studies included only antimicrobials; three included other drugs but separately reported 147 
antimicrobials.16,21,28  There was wide heterogeneity between studies in how data were 148 
generated and from which systems (Table 1). Ten used data from EP systems, one from an 149 
EHP system, and three from both.  Of the 14 studies, four combined data from EP and/or 150 
EHP systems with other electronic data: from the hospital information system,18, 28 laboratory 151 
system25,28 and an automated dispensing machine.18 Two further studies additionally used 152 
data from handwritten records.15,22 153 
The types of data used fell into three categories: 1) antibiotic prescribing or usage data (nine 154 
studies), 2) dose administration data (three studies), and 3) user log data (one study). 155 
Antibiotic usage data 156 
One of the two interventions based on SuD was an Australian study15 that used data 157 
generated from an EP system to audit doctors` antimicrobial prescribing choices according to 158 
local guidance and provide feedback to prescribers; the study did not reveal any significant 159 
change in prescribing practice. Others used EP and/or EHP systems to obtain data such as 160 
numbers of antimicrobial medication orders, dispensing volumes, course durations and doses, 161 
Page 8 of 35
Journal of Antimicrobial Chemotherapy: under review
Journal of Antimicrobial Chemotherapy
Confidential: for peer review only
 
either to evaluate interventions (all US studies),17-20 or to explore the use of the data for 162 
benchmarking or quality improvement, with studies from USA,25-26 Germany24  and South 163 
Korea.28 164 
Dose administration data 165 
The second study that evaluated an SuD intervention was a UK study of four sequential 166 
interventions, one of which involved a real time dashboard showing omission rates for 167 
antibiotics, non-antibiotics, and dietary supplements, plus weekly feedback emails. 168 
Introduction of the dashboard was associated with a significant reduction in the level 169 
(p=0.001) and trend (p<0.001) for antibiotic dose omission rates, using segmented regression 170 
analysis.16 A second UK study used EP data to explore use of antimicrobial dose omission 171 
data for benchmarking among hospitals.27 Two further studies focused on delays in dose 172 
administration and evaluated interventions to reduce time to administration of MRSA-173 
decolonizing therapy in a UK hospital23 and to reduce time to first dose of intravenous 174 
antimicrobials in a US hospital.22 175 
User log data 176 
A US study21 made use of user log data to evaluate how real-time surveillance dash-boards 177 
for high-risk medications (including aminoglycosides) were being used by pharmacists to 178 
inform clinical practice.  179 
Barriers 180 
Several studies15,21,22,24,26-28 suggested that data extraction was sometimes a complex or 181 
tedious process, often requiring informatics specialists, and that quality and completeness of 182 
information input into electronic systems was critical.15,21,24-25 The available data may not 183 
include all the information required, such as data required to assess outcomes or 184 
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appropriateness.16,17,24 Authors noted that systems were often localized, and so studies may 185 
not be generalizable to other hospital settings.21,23 Two studies took place across multiple 186 
sites with different EP systems; this contributed to increased complexity and additional data 187 
validation requirements.26-27 Baysari et al15 specifically recommended that vendors of EP 188 
systems could do more to facilitate generation of SuD from their systems.  189 
 190 
Discussion: 191 
Key findings 192 
We identified fourteen relevant studies, only two of which described interventions based on 193 
SuD.15,16 Others were descriptive or exploratory studies of SuD or used SuD to evaluate other 194 
interventions and suggest potential benefits in using such large datasets. Studies suggest that 195 
data extraction from EP and EHP was not straightforward, may require linkage of data from 196 
more than one system, and may be further limited by the quality of clinical information 197 
entered.  198 
Comparison with previous literature 199 
Previous ethnographic research29,30 has studied SuD for the purposes of driving 200 
improvements in quality and safety in healthcare more generally. One paper29 describes a 201 
study of an organisation that used SuD from an EP system to obtain real-time information on 202 
a variety of quality indicators and generate intelligence on performance of individuals, teams, 203 
and clinical services, as well as to identify and evaluate interventions. Measures such as the 204 
prevalence of omitted doses showed marked improvement. Potential unintended 205 
consequences were identified, including the risk of focusing attention on aspects of patient 206 
safety made visible by the system at the expense of less measurable issues. This issue was not 207 
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identified in our review, most likely due to different types of SuD and lack of studies using 208 
qualitative methods.  A second study30 identified that extra work was required for SuD, with 209 
ambiguity over who should be responsible for this extra work. While we identified that 210 
generation of useful data requires significant investment, appropriate infrastructure and 211 
dedicated informatics specialists, ambiguity around responsibility was not specifically 212 
identified, again likely to reflect the types of study included.  213 
Strengths and limitations 214 
Strengths include use of a systematic approach,14 including independent review of each stage 215 
of screening and data extraction. Limitations include the wide range of terms used in relation 216 
to SuD; this may account for two of the included studies17,22 being identified from reference 217 
lists of other publications and it is therefore possible that we missed further papers in our 218 
search. Other studies included insufficient detail as to how data were generated and had to be 219 
excluded.31-33 International variation in terminology and practice around EP and EHP systems 220 
also introduced challenges in interpreting the literature although we believe we were able to 221 
address these through the combined experience of our team. We did not formally assess risk 222 
of bias in included studies due to the heterogeneous nature of included studies and the paucity 223 
of interventions based on SuD. We did not identify any qualitative studies that met our 224 
inclusion criteria.  225 
Implications for practice  226 
National Institute for Health and Care Excellence (NICE) guidance on antimicrobial 227 
stewardship,34 which applies to England and Wales, lists EP as a specific area needed to drive 228 
quality improvement. Our work has identified that data suitable for secondary use is currently 229 
being generated from EP (and EHP) systems in hospital settings and is being used to identify 230 
areas for quality improvement and to monitor the impact of antimicrobial stewardship 231 
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initiatives. However, the best approaches to SuD are not yet clear. While the primary 232 
functions of EP/EHP systems receive considerable attention from vendors and 233 
implementation teams, the difficulties and challenges that some authors report in obtaining 234 
data for secondary use highlight the need for potential secondary uses to be considered. Data 235 
quality at point of input also constrains downstream opportunities for effective SuD, 236 
suggesting a need for local commitment to accurate data entry and quality assurance. 237 
Adequate investment in health service infrastructure (including informatics specialists) is 238 
required, with consideration to a whole healthcare economy approach. This may include 239 
linkage with other systems to aid assessment of antimicrobial choice. 240 
Implications for research 241 
We found that there is a lack of robust evidence around SuD as an intervention to improve 242 
antimicrobial stewardship; we found only two studies that tested intervention based on SuD, 243 
one of which demonstrated benefits in the outcome measure assessed16 and one of which did 244 
not15. There is therefore an urgent need for the public health and research community to 245 
target this topic, as currently very little information is available to help define, develop and 246 
implement interventions using SuD. Future evaluation of SuD interventions should include 247 
use of qualitative and mixed methods designs, in order to understand mechanisms and 248 
processes governing effective reuse of data, including enablers as well as barriers and the 249 
effects of local organisational context, in addition to impact upon outcomes. 250 
Conclusions: 251 
Our study suggests that the current paucity of evaluative interventional evidence may be due 252 
to immaturity in secondary use functions in current systems, which in turn hinders replication 253 
and evaluation of SuD for antimicrobial stewardship. SuD from EP and EHP systems may be 254 
useful to support or evaluate antimicrobial stewardship interventions in hospital settings.  255 
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However, SuD is often a complex process, especially where multiple systems are used, 256 
necessitating informatics specialists and careful consideration of data quality. Greater system 257 
functionality may also help realise the benefits. Studies of antimicrobial stewardship 258 
interventions based on SuD are lacking, representing a key area where future research is 259 
needed.  260 
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Table 1: Summary of included studies    388 
Study 
reference 
 
Study setting  
 
Study design, brief details and outcome 
measures where relevant 
Data used, system(s) from which obtained, 
and purpose of use 
Main findings 
Shojania et 
al,  1998[17] 
720 bed 
tertiary 
teaching 
hospital, USA 
Evaluation of randomised controlled trial of 
an intervention to improve vancomycin 
prescribing based on display of vancomycin 
guidelines within an EP system. Evaluation 
included uncontrolled before-and-after 
comparison of primary outcome measures 
(number and duration of vancomycin orders) 
and interrupted time series analysis of 
secondary outcome measures (number of 
patients who received at least one dose of 
vancomycin; amount of vancomycin 
dispensed), using retrospectively obtained 
data.  
Data from hospital pharmacy system and 
EP system (not specified) used to evaluate 
the effectiveness of the intervention over the 
9 month study period.  
The intervention resulted in a significant reduction in vancomycin use, 
with fewer orders and shorter duration of use.  The authors highlight a 
key limitation in that the data used to evaluate the effectiveness of the 
intervention did not allow assessment of appropriateness of use, nor 
identification of any adverse outcomes.   
Botwin et 
al, 2001[18]  
500 bed 
teaching 
hospital, USA 
Uncontrolled before and after study of an 
intervention aimed at reducing the duration 
of surgical prophylaxis, based on restricting 
nurses’ access to automated dispensing 
machines. Evaluated with uncontrolled 
before-and-after comparison using 
retrospectively obtained data to assess effect 
on outcome measure (compliance with 
policy) 
Data from the hospital pharmacy system 
(Digimedics) on course duration, together 
with data from Pyxis automated dispensing 
machines and hospital information system, 
used to evaluate the effectiveness of the 
intervention, with three months’ data 
extracted pre-intervention and a further three 
months’ data post-intervention.  
The 24hr stop-order policy for prophylactic antimicrobials was complied 
with in 31% of 137 cases pre-intervention and 63% of 146 cases post-
intervention, representing significant improvement.  No specific findings 
reported relating to the practicalities of secondary use of data for these 
purposes  
Hartmann 
et al, 2004. 
[24]
 
14-bed adult 
surgical ICU at 
a university 
hospital, 
Germany 
Retrospective descriptive analysis of data to 
explore feasibility of use for clinical audits 
and quality improvement as well as to 
explore whether using antibiotic therapy as a 
surrogate for infection correlates with 
mortality.  
Patient data management system used as an 
electronic patient record for surgical ICU 
patients, which included both EP and 
electronic medication administration records. 
Retrospective exploratory study, using 15 
months’ data on drug administrations, and 
the number and duration of courses, to 
explore how these data could be used.  
Of a total of 2,053 patients, 58.0% received antibiotics, with 36.7% 
receiving one antibiotic, 14.1% two antibiotics and 7.2% three or more. 
Duration of antibiotic (OR 1.46) and number of antibiotics used (OR 
2.15) significantly correlated with hospital mortality. Data interpretation 
was limited by the data being truncated if patients were transferred from 
the ICU to another ward, and by no data being recorded on indications for 
the antibiotics (e.g. prophylaxis, empirical or organism-specific 
treatment).  
Voit et al, 
2005. [25] 
Children’s 
hospital, USA, 
plus three 
matched 
hospitals 
Retrospective descriptive cohort study of 
1,493 children who underwent 1,630 
inpatient surgical procedures during a one-
year period, together with comparison to 
similar data obtained from three matched 
children’s hospitals, to identify opportunities 
for improving compliance with surgical 
prophylaxis protocols as the outcome 
measure.  
Data on administration and duration of 
antibiotics obtained from EP system 
(Meditech), plus patient and laboratory data 
from a second hospital system, and merged 
to create an electronic surveillance system.  
Data for a sample of 201 children were 
validated by chart review.  Equivalent details 
not given for the three matched hospitals. 
Retrospective exploratory study, using a 
year’s data, of whether these data could be 
used for quality improvement. 
Surgical antibiotic prophylaxis was not compliant with national guidance 
for nearly half of all procedures, most commonly involving prolonged 
antimicrobial administration in clean surgical procedures. Overall, 90% 
of procedures that were classified by the electronic surveillance system as 
opportunities for improvement at the index hospital were confirmed by 
medical chart review, suggesting reasonable validity. It was noted that 
antimicrobials may be used for indications that could not be captured by 
the dataset available, thus limiting the validity of the data. 
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Study 
reference 
 
Study setting  
 
Study design, brief details and outcome 
measures where relevant 
Data used, system(s) from which obtained, 
and purpose of use 
Main findings 
Sheen et al, 
2008.[28] 
1,080 bed 
tertiary 
teaching 
hospital, South 
Korea 
Retrospective, descriptive study of 
prescription and laboratory data for 56 drugs 
(including antimicrobials among other drugs) 
that may require dose adjustment in renal 
insufficiency.   
Four years’ data on drugs and doses obtained 
from EP system (not specified), together 
with data from laboratory system and 
hospital information system, and collated in 
a ‘data mart’. Retrospective exploratory 
study, with data used for descriptive analysis 
of overdose rates and identification of 
factors associated with overdose. 
A total of 28,954 patients were evaluated; 22,981 (5.3%) overdoses were 
identified from 431,991 medication orders for drugs that require dose 
adjustment in renal insufficiency.  Of the 20 most frequently overdosed 
drugs, 13 were antimicrobials.  Amoxicillin had the highest overdose rate 
(71.9% of all medication orders for amoxicillin were classed as 
overdoses, accounting for 6.9% of all overdoses), followed by 
piperacillin-tazobactam (10.3%; 6.9%) and cefotetan (9.8%; 5.4%).  It 
was noted that the secondary use of data allowed analysis of a very large 
dataset; limitations included that the dose administered may have differed 
from the dose prescribed but the database captured only the latter.   
Di Pentima 
et al, 
2010.[19] 
180 bed 
paediatric 
tertiary care 
teaching 
hospital, USA 
Uncontrolled before and after study of a suite 
of antimicrobial stewardship interventions 
aimed at reducing vancomycin use and 
vancomycin prescription errors. Effect on 
these two outcome measures evaluated using 
retrospectively obtained data. 
Data from EP system (Cerner) used to 
evaluate the effectiveness of the 
intervention. Four years’ data (one year 
baseline and three years’ post-intervention) 
obtained and used to assess monthly density 
of antimicrobial use, calculated as doses 
administered per 1,000 patient-days per year.   
Vancomycin utilisation significantly decreased from 378 doses 
administered per 1,000 patient days to 255 doses per 1,000 patient days in 
the last year of the study, representing a significant improvement despite 
an increase in S.aureus infections. The decrease in vancomycin use was 
not associated with increases in any other antibiotics. The rate of 
vancomycin prescribing errors also decreased. No specific findings 
relating to the secondary use of data for these purposes.   
Di Pentima 
et al, 
2011.[20] 
180 bed 
paediatric 
tertiary care 
teaching 
hospital, USA 
Uncontrolled before and after study of a suite 
of antimicrobial stewardship interventions. 
Effect on compliance with antimicrobial 
stewardship recommendations evaluated 
using retrospectively obtained data. 
Data from EP system (Cerner) used to 
evaluate the interventions. Data used to 
calculate annual data on doses administered 
per 1,000 patient-days over a six year period 
(three years baseline and three years post-
intervention).  
Rate of compliance with antimicrobial stewardship recommendations 
increased from 83 to 92% of interventions over three years. Total 
antimicrobial use peaked at 3,089 doses per 1,000 patient-days per year 
pre-intervention and decreased to 1,904 doses per 1,000 patient-days per 
year post-intervention. Authors noted as a limitation the lack of a 
standard metric for measuring antimicrobial use in children.  
Schwartz et 
al, 2011. [26] 
ICUs from four 
academic 
medical 
centres, USA 
Retrospective descriptive study with the aim 
of deriving and validating uniform ICU 
antimicrobial utilization measures based on 
computerized data. Electronic data were 
obtained and compared with observation and 
manual review of medication administration 
records to assess validity.   
Antimicrobial use data obtained from 
different systems: 
Hospital A: hospital pharmacy system and 
then EP data;  
Hospital B: data extracted from eMAR 
Hospital C: hospital pharmacy system 
Hospital D: EP data 
Exploratory study of data use for 
benchmarking, based on 36 months’ data. 
Bedside observations revealed more than 95% concordance between 
observed dose administrations and eMAR records. Comparison between 
manual record review and computerised data showed over-estimations in 
antimicrobial days and patient days on antimicrobials ranged from < 1% 
to 17.7% among study hospitals. The hospital for which numerator data 
were derived from eMAR had the least discrepant results. Programming 
of antimicrobial utilisation measures based on computerised pharmacy 
and administrative data was complex and error-prone. Problems 
commonly related to misunderstandings between programmers and 
investigators. The study highlights the complexity of generating reliable 
data from a diverse set of electronic medication systems. For example, 
eMAR data were available in a format amenable to analysis only at 
hospital B, which was able to distinguish antimicrobial doses that were 
administered from those that were ordered but not administered.  
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Study 
reference 
 
Study setting  
 
Study design, brief details and outcome 
measures where relevant 
Data used, system(s) from which obtained, 
and purpose of use 
Main findings 
Waitman et 
al, 2011. [21] 
University 
medical centre, 
USA  
Retrospective descriptive evaluation of a 
real-time monitoring and surveillance tool 
designed to identify patients at increased risk 
of an adverse drug event.  Includes analysis 
of 869 patients on aminoglycosides during a 
six month study period (as well as patients 
receiving warfarin and heparin/enoxaparin). 
Outcome measures based on pharmacist 
review of at-risk patients. 
Six months’ user log data obtained from EP 
(not specified) and used to evaluate the 
effectiveness of the surveillance tool in a 
descriptive evaluation.  
23 of 51 pharmacists used the aminoglycoside dashboard, which had a 
higher usage rate than those for warfarin and heparin/enoxaparin. All 
patients on aminoglycosides were reviewed at least once with a mean of 8 
reviews per case. Pharmacists generated comments for 100% of 
aminoglycoside patients, with more than three comments per case. 
Pharmacy comments were detailed, often summarizing patient, order and 
laboratory data. There were frequent interventions with relevant 
documentation reflecting the action taken. A limitation of the evaluation 
was that some pharmacists’ interventions may not have been documented 
and therefore could not be analysed. 
Panosh et 
al, 2012 [22] 
Adult patients  
admitted to  
cardiology, 
oncology or 
general 
medicine in a 
university 
hospital, USA 
Retrospective uncontrolled before and after 
study to evaluate the impact of introducing a 
direct ‘closed loop’ link between an EP 
system and a pharmacy order-entry system 
on the time to administer initial doses of 
intravenous antimicrobials. Evaluated using 
retrospectively obtained data. 
Data on the time of order entry were 
obtained retrospectively from the hospital 
pharmacy system (Horizon Meds 
Manager), based on data in the EP system 
(Horizon) and compared with handwritten 
administration times documented on 
medication administration records to 
evaluate the intervention. Used five months’ 
data pre-intervention and five months’ data 
post-intervention.  
Introduction of the closed loop link reduced the mean time to 
administration from 3.2 to 2.0 hours, representing a significant 
improvement. Limitations included: (1) handwritten antimicrobial 
administration times were sometimes documented in broad terms e.g. 
8am, 1pm rather than precise times; (2) documented administration times 
may not represent the time medication arrived from pharmacy; (3) they 
did not exclude doses administered in emergency department or as 
prophylaxis as this would have entailed the evaluation of data from 
multiple computer systems. 
Baysari et 
al,  2013[15] 
320 bed 
teaching 
hospital, 
Australia 
Uncontrolled before-and-after study of an 
audit and feedback intervention based on 
secondary use of data, exploring impact on 
compliance with antimicrobial policy 
relating to prescribing of restricted 
antimicrobials.  
Prescribing data (dose, duration, prescriber 
details) for selected restricted antimicrobials 
obtained from EP system (MedChart); data 
obtained each week, for the previous week, 
for 12 weeks, and used as part of the audit 
and feedback intervention. Evaluated using 
data on compliance with local antimicrobial 
policy and interviews with feedback 
recipients.  
 
No significant change in antimicrobial policy compliance following 
implementation of the intervention (0% of 20 relevant antibiotics had 
approval pre-intervention, and 11.9% of 101 post-intervention). 
Interviews revealed various practical problems with the policy. 
Determining the indication for each antimicrobial proved to be 
challenging as prescribers rarely documented indications for use. It was 
noted that data extraction was not easy and that greater system 
functionality was required to enable data to be extracted for real time 
review and feedback.  
Carruthers 
et al, 
2013[27]  
Three hospitals 
with 1234, 424 
and 1472 beds 
respectively,  
UK 
Descriptive time series analysis of data on 
omitted doses of antibiotics in three hospitals 
using EP.  
One year’s data extracted retrospectively 
from each of the three EP systems (Hospital 
1: locally developed Prescribing 
Investigation and Communications System; 
Hospital 2: Meditech; Hospital 3: JAC). 
Exploratory study; data used for 
benchmarking.  
The rate of omitted antibiotic doses ranged from 5.9% of 448,716 
prescribed doses in one hospital to 10.3% of 573,538 in another. The 
percentage of missed doses with no recorded reason varied from 26.7% at 
one hospital to 61.7% at another. The study demonstrated that large data 
sets from different EP and medicines administration systems can be used 
to quantify the incidence of omitted antibiotic doses. A limitation is that 
some clinical areas in the study hospitals did not use EP. 
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Study 
reference 
 
Study setting  
 
Study design, brief details and outcome 
measures where relevant 
Data used, system(s) from which obtained, 
and purpose of use 
Main findings 
Coleman et 
al, 2013 [16] 
1200 bed 
teaching 
hospital, UK 
Retrospective time-series analysis of data on 
omitted doses of all medications; four 
sequential interventions introduced. 
239 weeks’ data on omitted doses extracted 
retrospectively from EP (locally developed 
Prescribing Investigation and 
Communications System). Data for 
antibiotics presented separately.  Data used 
to evaluate a series of four sequential 
interventions, one of which was based on 
secondary use of data and involved a real 
time dashboard intervention showing 
omission rates for antibiotics, non-
antibiotics, and dietary supplements, plus 
weekly feedback emails.  
Omission rates for antibiotics reduced from 10.3 to 4.4% of doses over 
the period of the study, a reduction of 57% (p<0.001). Introduction of the 
dashboard was specifically associated with a significant reduction in the 
level (p=0.001) and trend (p<0.001) for missed antibiotic doses, using 
segmented regression analysis. Rates of omitted antibiotic doses also 
decreased significantly following the instigation of executive-led overdue 
doses root cause analysis meetings and the publication of an associated 
Rapid Response Alert. Implementing a visual indicator for overdue doses 
was not associated with a significant change. Limitations noted include 
possible documentation discrepancies and the inclusion of ‘legitimate’ 
omissions such as patient refusal in the dataset.  
Brooks et 
al, 2014 [23] 
1,200 bed 
teaching 
hospital, UK 
Retrospective time series analysis of time 
between hospital admission and first 
administration of MRSA decolonisation 
therapy for patients colonised with MRSA. 
Six years’ data on time of administration 
of MRSA decolonization therapy obtained 
retrospectively from EP (locally developed 
Prescribing Investigation and 
Communications System). Data used to 
evaluate any changes following various 
national and local interventions. 
Of a 1,403 identified cases, 94% had the time of hospital admission and 
time of first administration of MRSA decolonisation therapy documented.  
Significant decrease of 15% per year (95% CI: 11.1-18.7%) in time from 
patient admission to administration of decolonisation treatment for 
MRSA positive patients. It was noted that MRSA bacteraemia cases had 
to be excluded as a result of differences in the time needed for 
colonization and bacteraemia samples to be cultured in the laboratory. 
Studies are presented in chronological order. Abbreviations: eMAR: electronic medication administration record; CI: confidence interval; EP: electronic prescribing; ICU: intensive care unit; VRE: vancomycin-389 
resistant Enterococci 390 
 391 
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Figure 1: PRISMA flow chart 393 
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Records excluded based on 
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(n=2,239) 
Full-text articles assessed 
for eligibility (n = 92)  
Full-text articles excluded (n = 80) 
Policies, reviews, commentaries 
(27) 
Other data sources (17) 
Disease-focused (3) 
Not antimicrobials (6) 
Not secondary use of data (24) 
Not quality related (1) 
Non-hospital settings (2) 
Studies included in review  
(n = 14) 
Additional records 
identified from 
bibliographies of full-text 
articles (n = 2) 
Studies meeting inclusion 
criteria (n = 12) 
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Table S1: Keywords used for search strategy in all 4 databases (NB: ‘adj’ function used in Medline 
and Embase only, for IPA and CINAHL ‘adj’ was substituted with ‘N’) 
Keywords in 4 different databases: 
Facet: Keywords used: Number of 
articles 
retrieved 
from Embase 
and Medline  
Number of 
articles 
retrieved 
from Cinahl 
Number of 
articles 
retrieved 
from IPA 
Facet 1: 
Electronic 
data 
systems and 
surveillance 
Secondary* data* or Secondary* 
use* or Secondary* adj4 data* or 
secondary* adj3 EHR* or secondary* 
adj3 electronic* health* record*.  
63,778 17,643 13,280 
Surveillance* adj3 information* 
system* or ((computer* or 
electronic*) adj3 (detect* or 
surveillance*)) or Medication* adj1 
monitor* or Medicine* adj1 monitor* 
or Technovigilance* or Computer* 
adj4 surveillance* or Computer* adj4 
monitor* 
Electronic* prescri* or E-Prescri* or 
ePrescri* or prescri* adj3 data* or 
Decision* support* system* or 
Computer* prescri* support* 
system* or Computer* adj3 prescri* 
or electronic* adj3 prescri* or 
Automat* prescri* or Prescri* 
automat* screen* system* 
Computer* information* or 
Computer* adj4 Adverse* drug* or 
Computer* adj4 patient* 
information* 
Computer* physician* decision* 
support* or CPOE or Computer* 
physician* order* or physician* 
order* entry* or Computer* 
provider* order* or provider* order* 
entry* or Computer* prescriber* 
order* or prescriber* order* entry* 
or Computer* prescription* order* or 
prescription* order* entry* or 
Medication* order* entry* or 
Medicine* order* entry* or 
drug*order* entry* 
 dispen* adj2 data* or Hospital* 
dispen* or Pharmacy* adj2 dispen* 
or Clinic* adj2 information* system* 
or computer* pharmacy* record*  
Electronic* medication* adj1 
administration* record*or 
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Electronic* medication* adj1 
administration* system* or 
Electronic* drug* adj1 
administration* record* or 
Electronic* drug* adj1 
administration* system* or 
administration* data* or Medication* 
administration* system* or EPMA* or 
EMAR* 
hospital* computer* program* or 
hospital* information* system* or 
hospital* data* or electronic* health* 
record* or electronic* clinical* 
system* or pharmacy* computer* 
system* 
 (Electronic* or computer*) adj2 
discharg* or ((electronic* database*) 
and (clinical* data*))  
((pharmacy* or medication* or 
medicine*) adj1 (system*or data*) 
and (monitor* or access* or assess* 
or surveillance* or vigilance* or 
collect* or review* or identif* or 
analys* or examin* or investigat* or 
intervention* or compare*))  
 
Facet 2: 
Anti-
infective 
Healthcare* associa* infection* or 
health* care* associa* infection* or 
healthcare* relat* infection* or 
health* care* relat* infection* or 
hospital* associa* infection* or 
hospital* relat* infection* or 
hospital* acquire* infection* or anti-
microbial* or antimicrobial* or 
antibiotic* or anti-infective* or anti* 
infective* or anti-viral* or anti* viral* 
754,021 36,245 39,164 
  
Facet 3: 
Quality and 
safety 
quality* adj2 safety* measurement* 
or quality* adj2 healthcare* or 
quality* adj2 health* care* or 
quality* improvement* or patient* 
safety* or (improv* quality* adj2 
(efficiency* or care* or safety*)) or 
improv* care* or Prevent* adj2 
harm* or Reduc* adj2 harm* or 
Safety* adj1 Improv*  
121,858 95,547 10,713 
     
Facet 4: 
Hospital 
Hospital* or Tertiary* care* or 
Secondary* care* or acute* care* or 
Inpatient* or ward* or emergency* 
department* or secondary* 
2,402,529 300,832 78,512 
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healthcare* or tertiary* healthcare* 
or intensive* care* unit* or ICU or 
ITU or critical* care* unit* 
     
Facet 5: (secondary* use* adj4 
data*).ti,ab,kw. 
221 19 1 
Search 
combination 
Facet combination: 1 and 2 and (3 or 
4) or 5 
1121 
(15/08/2014) 
269 
(15/08/2014) 
707 
(15/08/2014) 
 
MeSH terms used for search strategy in Embase 
EMBASE search: 
Facet: Boolean 
term 
used: 
MeSH Term Total number 
of articles 
found with 
each facet 
from 
15/08/2014 
search 
1). Electronic 
data systems 
and 
surveillance 
OR electronic prescribing/ Number of 
articles found 
after all the 
MeSH terms in 
facet 1 
combined:  
44,462 
OR computerized provider order entry/ 
OR Electronic medical record/ 
OR *hospital information system/ 
OR *Decision support system/ 
OR (medical audit/ or feedback system/) and 
(information system/) 
OR computer assisted drug therapy/ 
 
2). Anti-
infective 
OR Exp antiinfective agent/ Number of 
articles found 
after all the 
MeSH terms in 
facet 2 
combined:  
2,448,322 
OR Healthcare associated infection/ 
OR Hospital infection/ 
OR *infection/ 
 
3). Quality and 
safety 
OR *Risk reduction/ Number of 
articles found 
after all the 
MeSH terms in 
facet 3 
combined: 
130,050 
OR *Healthcare quality/ 
OR *Patient safety/ 
OR Quality Improvement/ 
OR *Risk management/ 
OR *Risk assessment/  
 
4). Hospital OR hospital/ Number of 
articles found 
after all the 
OR secondary health care/ 
OR tertiary health care/ 
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OR Hospital discharge MeSH terms in 
facet 4 
combined: 
451,936 
OR hospital patient/ 
 
Search 
combination 
 [Facet 1 and facet 2 and (facet 3 or facet 4)] 533 
 
MeSH terms used for search strategy in Medline 
Medline search: 
Facets: Boolean 
term 
used: 
MeSH Term Total number 
of articles 
found with 
each facet 
from 
15/08/2014 
search 
1). Electronic 
data systems 
and 
surveillance 
OR Clinical pharmacy information systems/ Number of 
articles found 
after all the 
MeSH terms in 
facet 1 
combined: 
15,794 
 
 
 
OR Electronic prescribing/ 
OR *Decision Support Systems, Clinical/ 
OR Decision Making, Computer-Assisted/ 
OR Drug Therapy, Computer-Assisted/ 
OR (information systems/) and (clinical audit/ or 
Medical audit/ or feedback/) 
OR Medical order entry systems/ 
OR Electronic Health Records/ 
 
2). Anti-
infectives 
OR community-acquired infections/ or cross infection/ Number of 
articles found 
after all the 
MeSH terms in 
facet 2 
combined: 
1,322,236 
OR Exp antiinfective agent/ 
OR *infection/ 
 
3). Quality and 
safety 
OR *Safety management/ Number of 
articles found 
after all the 
MeSH terms in 
facet 3 
combined: 
72,818 
OR *Quality of healthcare/ 
OR *Patient safety/ 
OR Quality Improvement/ 
OR *Risk management/ 
OR *Risk assessment/ 
 
4). Hospital OR Hospitals/ Number of 
articles found 
after all the 
MeSH terms in 
OR Secondary Care/ 
OR Tertiary Healthcare/ 
OR Inpatients/  
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  Patient discharge/  facet 4 
combined: 
84,736 
Search 
combination 
 [Facet 1 and facet 2 and (facet 3 or facet 4)] 41 
 
MeSH terms used for search strategy in CINAHL 
CINAHL search: 
Facet: Boolean 
term 
used: 
MeSH Term Total number 
of articles 
found with 
each facet 
from 
15/08/2014 
search 
1). Electronic 
data systems 
and 
surveillance 
OR Electronic order entry Number of 
articles found 
after all the 
MeSH terms in 
facet 1 
combined:  
10,359  
OR *Computerised patient record 
OR *Nursing information systems 
OR *hospital information systems 
OR Clinical pharmacy information systems 
OR (Audit or feedback) and information systems 
OR *decision support systems, clinical  
OR *data collection, computer assisted 
 Drug therapy computer assisted  
 
2). Anti-
infectives 
OR MH "Antiinfective Agents+" Number of 
articles found 
after all the 
MeSH terms in 
facet 2 
combined:  
121,409 
OR MH "Community-Acquired Infections+" 
OR MH "Cross Infection+" 
OR MH "Infection+" 
 
3). Quality and 
safety 
OR *quality of healthcare / Number of 
articles found 
after all the 
MeSH terms in 
facet 3 
combined: 
64,390 
OR *Patient safety/ 
OR Quality Improvement/ 
OR *Risk management/ 
OR *Risk assessment/  
 
4). Hospital OR Hospital units/ Number of 
articles found OR secondary health care/ 
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OR tertiary health care/ after all the 
MeSH terms in 
facet 4 
combined: 
61,176 
OR Transfer discharge/ 
OR inpatients/ 
    
Search 
combination 
 [Facet 1 and facet 2 and (facet 3 or facet 4)] 49 
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Table S2: Inclusion and Exclusion Criteria  
Inclusion Criteria Exclusion  Criteria 
Hospital focused research – includes inpatients, outpatients, 
and/or discharge. Also includes community hospitals and 
Outpatient Parenteral Antimicrobial Therapy from hospitals.   
Any non-hospital based setting e.g. primary care, care/nursing homes 
(includes long-term care facilities), state agencies, clinical registries, 
clinical trials of drugs, out-of-hours centres, general practices and 
private offices (clinics).  
Data used from electronic prescribing and/or hospital 
pharmacy data systems(s), either alone or in combination with 
other data. Electronic prescribing systems were taken to include 
the prescribing component of computerised prescriber order entry 
(CPOE) systems that may allow ordering of tests and treatment 
other than medication, as well as any medication administration 
data obtained from electronic prescribing systems. 
Non-electronic surveillance/monitoring data collection methods 
Electronic databases looking at surveillance of diseases (including 
infectious diseases) and epidemiological investigations without any 
mention of antimicrobials, prevalence studies of diseases, human 
factors studies, links between two or more diseases, patient costs, 
animal studies, pharmacokinetic or pharmacodynamics studies, 
pharmacovigilance reports, studies of non-prescribed medication, 
post-marketing drug surveillance and electronic systems intended for 
non-healthcare professionals. 
If a study did not include information on how electronic data has been 
generated, then the study was excluded 
Focuses on secondary use of data (defined as the reuse of 
aggregated electronic [clinical or operational] data from an 
electronic prescribing or electronic hospital pharmacy system 
for purposes other than direct patient care or for its original 
purpose).   
 
The following were excluded: 
• Trigger tools * (includes electronic tools and alerts) 
• Bar code technologies, including Bar Code Medication 
Administration (BCMA) systems  
• Medical Devices, e.g. smart pumps, infusion devices, unit-
dose systems, IV drug-delivery systems, being used for 
their primary purpose 
• Incident reporting systems (these fulfil their primary 
purpose which is to reduce errors and raise awareness, 
hence will be excluded in this systematic review) 
• Studies describing the development or evaluation of 
clinical decision support systems (CDSS) and alerts, in-
built as part of the CDSS software. CDSS is defined as 
“software that is designed to be a direct aid to clinical 
decision-making, in which the characteristics of an 
individual patient are matched to a computerized clinical 
knowledge base and patient-specific assessments or 
recommendations are then presented to the clinician or the 
patient for a decision”**.However, any research articles 
which are based on the secondary use of data from 
CDSS/alerts systems which otherwise meet the inclusion 
criteria will be included.  
• Studies based solely on electronic hospital/pharmacy data 
being used for direct patient care, such as to identify lists of 
patents for clinical pharmacists’ follow up, were excluded.  
 
Original research conducted in any country  Papers that were not original research e.g. reviews, Conference 
Proceedings, Editorials, Case-reports, Book Chapters, Extracts, Notes 
(unless original research is presented), Case-studies at the individual 
patient level (case-studies on a hospital or similar level are included),  
Policy and opinion papers (includes commentaries), and letters to the 
Editor were excluded 
Research papers available in English  
  
Full text article unavailable in English  
Includes data on ANTIMICROBIAL use (prescribing, 
administration, transcription, monitoring, dispensing, overall 
hospital use, antimicrobial safety/use in general) 
Studies focusing on a wider range of medications are included, 
if data specific to one of more antimicrobials were reported 
separately 
Research that did not present data for antimicrobials  
Quality outcomes measured in the study clearly defined 
AND/OR a qualitative study examining secondary use of data  
None of the outcome measures are related to antimicrobial medication, 
use or safer use of  antimicrobial medication 
Research in adults and/or paediatrics and/or neonates and 
includes any aspect of prophylaxis and/or treatment with 
antimicrobials 
 
* where trigger tools are defined as the use of sets of triggers or ‘clues’, to identify patients who may have suffered adverse events (ADEs) 
either in real time or retrospectively. ** Adapted from Sim I, Gorman P, Greenes RA et al.  Clinical decision support systems for the 
practice of evidence-based medicine. J Am Med Inform Assoc. 2001 ;8(6):527-34. 
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JAC-2016-1716 
The secondary use of data from hospital electronic prescribing and pharmacy systems to support the 
quality and safety of antimicrobial use: a systematic review 
 
COMMENTS to the Author RESPONSES 
Editor (Dr Hayley Wickens): 
 
Thank you for submitting this interesting review of published 
data on use of data from electronic prescribing and pharmacy 
systems; the paucity of information did not come as a surprise, 
but was somewhat disappointing.   
 
The paper is well-written and robust methodologically, and 
suitable for publication, subject to addressing the queries 
raised by the reviewers.  
 
I agree that Table 1 should remain in the main body of the 
paper, as it describes the findings and will be useful for 
readers. 
 
 
Thank you for these positive comments 
 
 
 
 
 
 
 
 
We have left table 1 in the main body of the manuscript as 
suggested.  
Supplementary Revision 
 
As mentioned in the revision e-mail sent by the Editor, Dr 
Wickens, (on 20th January 2017) this document contains 
specific style requirements and editorial office comments, 
which MUST be addressed when you prepare your revised 
paper.  
 
 
 
IMPORTANT ADVICE: 
 
By far the most common proof problems that we have to 
contact authors about concern a lack of consistency in the 
numbers of things (patients or isolates for instance) stated in 
different parts of the article (for example the Abstract might 
state that there were 46 isolates, but in Table 1 only 40 are 
listed and so on).  
 
Other common related faults are lists of items in the text or 
Tables that don’t add up to the total that is stated, or 
percentages that don’t match the numbers indicated. We 
understand that articles undergo many rounds of revision 
before submission and it is easy for these types of 
inconsistencies to creep in.  
 
Now is the best time to take a fresh look at your article, sit 
down with a calculator and check: (i) that everything is 
consistent throughout the Abstract, main text, Figures and 
Tables; (ii) that everything adds up to the correct totals; and 
(iii) that percentages are correct. 
 
Please make good use of what may be your final 
opportunity to check your article and make any 
corrections or redraft portions of the text, Tables or 
Figures before resubmission. THIS IS EXTREMELY 
IMPORTANT AS EXTENSIVE OR TRIVIAL 
REDRAFTING OF ARTICLES AT THE PROOF STAGE 
IS NOT PERMITTED. 
 
 
We have read the paper carefully as advised.  
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Specific Comments 
 
Please move the Figure to the end of the article, after the 
Reference list and Table. 
 
 
 
 
 
We have moved the figure as requested.  
 
TITLE PAGE DETAILS AND ABSTRACT FORMAT 
 
On the title page, please: 
-give a short running title (<50 characters in total). 
 
-remove the keywords as JAC no longer requires these. 
 
-indicate the corresponding author in the list with an asterisk. 
 
 
To make it easier to index your article, please put family 
names of all authors in CAPITALS. 
 
 
 
 
 
A running title has been added as requested. 
 
The keywords have now been removed. 
 
An asterisk has been added to indicate the corresponding 
author. 
 
The family names of all authors have been capitalised as 
requested. 
 
REFERENCE CITATIONS 
 
References must be cited in the text in numerical order.  
Currently, your reference citations skip from 15 to 22. 
 
 
 
 
We have amended the referencing to ensure that all are 
now given in numerical order. 
 
MAIN TEXT 
 
OR & MRSA are allowed abbreviations. 
 
 
 
 
We have removed the explanation of these two 
abbreviations from the paper. 
 
ACKNOWLEDGEMENTS/FUNDING/CONFLICTS OF 
INTEREST 
 
Please move the ‘Acknowledgements’ section to before the 
‘Funding’ section. 
 
 
Transparency declarations: Please note that the declaration 
MUST cover ALL the authors. You may need to add ‘All 
other authors: none to declare’ to achieve this. 
 
 
Please ensure that your Transparency declarations are still up 
to date. For more information please see the relevant section 
of our Instructions to Authors 
(http://www.oxfordjournals.org/jac/for_authors/index.html) 
for further details. 
 
 
 
 
The acknowledgements section has been moved as 
requested.  
 
 
 
We have added this extra clarification to the transparency 
declaration and can confirm that this section remains up 
to date.  
 
REFERENCES 
 
References to websites. Please check that the URL listed 
works and leads to the material you have indicated. 
 
 
 
We have checked all URLs and can confirm that they are 
active (as at 25 January 2017) 
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FIGURES AND TABLES 
 
Table formatting 
Please note that Tables should not contain return characters 
that have been used to create line breaks. Each data item 
should be in a separate cell. If you have used return characters 
to create line breaks you will need to add rows to your Table 
in order to remove the return characters. 
 
 
 
 
We have amended the table slightly to remove return 
characters.  
Referee: 1: 
 
 
Interesting (and disppointing) finding that electronic 
prescribing and data systems might not be as useful as one 
would want them to be for secondary  use of data. 
 
Did you identify the reasons why the 2 articles sourced from 
bibliography were missed in the searches? An explanation 
might fit in the limitations. 
 
 
 
We agree that this was disappointing!  It does however 
represent a considerable opportunity for research and 
development, which we emphasise in the paper. 
 
This is an interesting point; we suspect this relates to the 
diffuse terminology in this field.  We have added a point to 
this effect in the strengths and limitations section; we have 
also indicated in the results section of the paper which two 
papers these were in order to aid transparency in this 
respect.  
 
Line 191-200 appropriatness would need a reference to the 
indication for prescription so it should be highly 
recommended in any new EP software, right?  
 
This would help Sud, right? 
 
 
 
 
 
 
 
 
Unfortunately only 2 studies reported on interventions based 
on SUDs. 
 
 
 
As well as the indication, an assessment of 
appropriateness is likely to need other information such as 
allergies, concomitant drugs (as anti-infective choices may 
depend on drug interactions) and concomitant co-
morbidities. This is likely to need to go beyond a 
requirement for indication for anti-infectives prescribed 
using EP systems and will require data linkage between 
systems beyond EP and EHP systems; we have now 
highlighted in this in the discussion section.  
 
 
 
 
We already highlight the limitation that only two studies 
reported interventions based on SuD; we have now added 
the word “only” to make this more explicit.  
 
In the coclusions and recommendations it might be reasonable 
to suggest that: 
1; EP and EHP systems should be able to identify targets for 
quality improvement (Stewardship Targets) 
 
 
2) EP and EHP systems should have algorithms, based on 
locally followed guidelines so that data entry is not free text so 
as to avoid missing or inaccurate or incomplete data entry. In 
addition the indication (diagnosis) should also ideally be part 
of the electronic prescription so as to allow for evaluation of 
appropriateness, right?  
 
Thank you for these suggestions.  
1) We have added a comment to this effect.  
2) The included studies did not suggest that free text 
data entry was a problem, so while this would be 
a common sense recommendation, we do not feel 
that it is appropriate to make this point based on 
the evidence that we reviewed. We have 
responded to the point around evaluation of 
appropriateness above. 
 
 
 
Referee: 2: 
 
 
I believe that this article is timely due to the current move to 
incorporate electronic prescribing data into hospital-based 
quality and safety initiatives. I have a couple of comments that 
maybe the authors could take into consideration. 
 
 
Thank you for these positive comments. 
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I envision that healthcare professionals who would read this 
article would be interested in utilising secondary data as part 
of their antimicrobial stewardship programmes, therefore I 
would like to see some discussion about the enablers related to 
SuD presented as well as barriers. I think that it is important to 
present a balanced argument for readers who are interested in 
SuD.  
We have added a recommendation that future work 
should explore the facilitators as well as barriers to 
secondary use of data.  
 
Also, I understand that there is a restriction on the word count 
but I believe that some discussion on whether the types of data 
used in the studies were effective in improving antimicrobial 
stewardship in hospitals.  
 
 
For example, were there any positive changes in prescribing 
behaviour due to the SuD analysis?  Were there any 
implications for implementing and sustaining good 
stewardship? I think that these poi ts would of interest to 
those who would read this article. 
 
 
 
This information is included within table 1.  As highlighted, 
we found only two intervention studies that were designed 
to answer the question around whether secondary use of 
data is helpful; this information is presented in table 1 and 
in the text of the paper.  
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